Fengyun Zhong, Yilin Lin, Long Zhao, Changjiang Yang, Yingjiang Ye, Zhanlong Shen
No abstract text is available yet for this article.
June 1, 2023: British Journal of Cancer
Rebecca L McCarthy, Ellen Copson, William Tapper, Helen Bolton, Alex H Mirnezami, J Robert O'Neill, Nimesh N Patel, Marc Tischkowitz, Ramsey I Cutress
Identifying healthy carriers of germline pathogenic variants in high penetrance cancer susceptibility genes offers the potential for risk-reducing surgery. The NHS England National Genomic Test Directory offers germline and somatic testing to patients with certain cancers or rare and inherited diseases, or, in some cases, to their relatives. This review summarises current UK guidelines for risk-reducing surgical interventions available for individuals with no personal history of cancer, who are determined to carry germline pathogenic variants...
May 31, 2023: British Journal of Cancer
Anthony B El-Khoueiry, James Clarke, Tobias Neff, Tim Crossman, Nirav Ratia, Chetan Rathi, Paul Noto, Aarti Tarkar, Ignacio Garrido-Laguna, Emiliano Calvo, Jordi Rodón, Ben Tran, Peter J O'Dwyer, Adam Cuker, Albiruni R Abdul Razak
BACKGROUND: GSK3368715, a first-in-class, reversible inhibitor of type I protein methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This Phase 1 study (NCT03666988) evaluated safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of GSK3368715 in adults with advanced-stage solid tumors. METHODS: In part 1, escalating doses of oral once-daily GSK3368715 (50, 100, and 200 mg) were evaluated. Enrollment was paused at 200 mg following a higher-than-expected incidence of thromboembolic events (TEEs) among the first 19 participants, resuming under a protocol amendment starting at 100 mg...
May 26, 2023: British Journal of Cancer
Arielle van Mourik, Gina Tonkin-Hill, John O'Farrell, Shohei Waller, Lavinia Tan, Richard W Tothill, David Bowtell, Stephen Fox, Andrew Fellowes, Clare Fedele, Penelope Schofield, Tharani Sivakumaran, Hui-Li Wong, Linda Mileshkin
BACKGROUND: Diagnosis and management of cancers of unknown primary (CUP) remain challenging. This study examines the referral patterns, management and outcomes of patients referred to Australia's first dedicated CUP clinic. METHODS: Retrospective medical record review was conducted for patients seen at the Peter MacCallum Cancer Centre CUP clinic between July 2014 and August 2020. Overall survival (OS) was analysed for patients with a CUP diagnosis where treatment information was available...
May 24, 2023: British Journal of Cancer
Lorna McWilliams, Helen Ruane, Fiona Ulph, Victoria G Woof, Fiona Harrison, D Gareth Evans, David P French
BACKGROUND: Risk-stratified screening is being considered for national breast screening programmes. It is unclear how women experience risk-stratified screening and receipt of breast cancer risk information in real time. This study aimed to explore the psychological impact of undergoing risk-stratified screening within England's NHS Breast Screening Programme. METHODS: Individual telephone interviews were conducted with 40 women who participated in the BC-Predict study and received a letter indicating their estimated breast cancer risk as one of four risk categories: low (<2% 10-year risk), average (2-4...
May 24, 2023: British Journal of Cancer
Crystal S Langlais, Rebecca E Graff, Erin L Van Blarigan, John M Neuhaus, Janet E Cowan, Jeanette M Broering, Peter Carroll, Stacey A Kenfield, June M Chan
BACKGROUND: Individual behaviours are associated with prostate cancer (PC) progression. Behavioural scores, comprised of multiple risk factors, allow assessment of the combined impact of multiple behaviours. METHODS: We examined the association between six a priori scores and risk of PC progression and mortality among 2156 men with PC in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) cohort: two scores developed based on the PC survivorship literature ('2021 Score [+ Diet]'); a score developed based on pre-diagnostic PC literature ('2015 Score'); and three scores based on US recommendations for cancer prevention ('WCRF/AICR Score') and survival ('ACS Score [+ Alcohol]')...
May 22, 2023: British Journal of Cancer
Nitya Raj, Jennifer A Chan, Stephanie J Wang, Rahul R Aggarwal, Susan Calabrese, April DeMore, Lawrence Fong, Jennifer Grabowsky, Thomas A Hope, Kanti Pallav Kolli, Claire K Mulvey, Pamela N Munster, Kimberly Perez, Sippy Punn, Diane Reidy-Lagunes, Sofia Von Fedak, Li Zhang, Emily K Bergsland
BACKGROUND: To date, single-agent immune checkpoint inhibitor (CPI) therapy has proven to be ineffective against biomarker-unselected extrapulmonary poorly differentiated neuroendocrine carcinomas (EP-PDNECs). The efficacy of CPI in combination with chemotherapy remains under investigation. METHODS: Patients with advanced, progressive EP-PDNECs were enrolled in a two-part study of pembrolizumab-based therapy. In Part A, patients received pembrolizumab alone. In Part B, patients received pembrolizumab plus chemotherapy...
May 19, 2023: British Journal of Cancer
Marianna Aprile, Simona Cataldi, Caterina Perfetto, Antonio Federico, Alfredo Ciccodicola, Valerio Costa
BACKGROUND: B-raf inhibitors (BRAFi) are effective for BRAF-mutated papillary (PTC) and anaplastic (ATC) thyroid carcinomas, although acquired resistance impairs tumour cells' sensitivity and/or limits drug efficacy. Targeting metabolic vulnerabilities is emerging as powerful approach in cancer. METHODS: In silico analyses identified metabolic gene signatures and Hif-1α as glycolysis regulator in PTC. BRAF-mutated PTC, ATC and control thyroid cell lines were exposed to HIF1A siRNAs or chemical/drug treatments (CoCl2 , EGF, HGF, BRAFi, MEKi and diclofenac)...
May 17, 2023: British Journal of Cancer
Charlotte Salmon, Amélie Quesnel-Vallée, Tracie A Barnett, Andrea Benedetti, Marie-Soleil Cloutier, Geetanjali D Datta, Yan Kestens, Belinda Nicolau, Marie-Élise Parent
BACKGROUND: Striking geographic variations in prostate cancer incidence suggest an aetiological role for spatially-distributed factors. We assessed whether neighbourhood social deprivation, which can reflect limited social contacts, unfavourable lifestyle and environmental exposures, is associated with prostate cancer risk. METHODS: In 2005-2012, we recruited 1931 incident prostate cancer cases and 1994 controls in a case-control study in Montreal, Canada. Lifetime residential addresses were linked to an area-based social deprivation index around recruitment (2006) and about 10 years earlier (1996)...
May 15, 2023: British Journal of Cancer
Jun-Hong Guo, Yu-Shui Ma, Jie-Wei Lin, Geng-Xi Jiang, Juan He, Hai-Min Lu, Wei Wu, Xun Diao, Qi-Yu Fan, Chun-Yan Wu, Ji-Bin Liu, Da Fu, Li-Kun Hou
BACKGROUND: Large cell lung carcinoma (LCLC) is an exceptionally aggressive disease with a poor prognosis. At present, little is known about the molecular pathology of LCLC. METHODS: Ultra-deep sequencing of cancer-related genes and exome sequencing were used to detect the LCLC mutational in 118 tumor-normal pairs. The cell function test was employed to confirm the potential carcinogenic mutation of PI3K pathway. RESULTS: The mutation pattern is determined by the predominance of A > C mutations...
May 13, 2023: British Journal of Cancer
Hyung-Don Kim, Changhoon Yoo, Min-Hee Ryu, Yoon-Koo Kang
BACKGROUND: Imatinib re-challenge is one of the available therapeutic options for patients with treatment-refractory gastrointestinal stromal tumours (GIST). Intermittent dosing of imatinib was suggested to delay outgrow of the imatinib-resistant clones in a preclinical study, and it could potentially reduce the adverse events. METHODS: A randomised phase 2 study was performed to evaluate the efficacy and safety of a continuous or intermittent imatinib schedule in GIST patients whose disease had progressed to at least imatinib and sunitinib...
May 13, 2023: British Journal of Cancer
Seohyuk Lee, Chao Ma, Qian Shi, Jeffrey Meyers, Pankaj Kumar, Felix Couture, Philip Kuebler, Smitha Krishnamurthi, DeQuincy Lewis, Benjamin Tan, Eileen M O'Reilly, Anthony F Shields, Jeffrey A Meyerhardt
BACKGROUND: We sought to assess the influences of sleep duration, sleep adequacy, and daytime sleepiness on survival outcomes among Stage III colon cancer patients. METHODS: We conducted a prospective observational study of 1175 Stage III colon cancer patients enrolled in the CALGB/SWOG 80702 randomised adjuvant chemotherapy trial who completed a self-reported questionnaire on dietary and lifestyle habits 14-16 months post-randomisation. The primary endpoint was disease-free survival (DFS), and secondary was overall survival (OS)...
May 13, 2023: British Journal of Cancer
Apostolia Maria Tsimberidou, Claire F Verschraegen, Robert Wesolowski, Chi-Sheng Shia, Pei Hsu, Tillman E Pearce
BACKGROUND: Report of a Phase 1 dose-escalation study of OBI-3424 monotherapy in patients with advanced solid tumors (NCT03592264). METHODS: A classic 3 + 3 design was used to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D) of OBI-3424 administered intravenously, as a single agent, at doses of 1, 2, 4, 6, 8, or 12 mg/m2 (days 1 and 8 of a 21-day cycle, Schedule A) or 8, 10, 12, or 14 mg/m2 (day 1 of a 21-day cycle, Schedule B)...
May 12, 2023: British Journal of Cancer
Qian Cheng, Shanglei Ning, Lei Zhu, Changlu Zhang, Shaodong Jiang, Yajing Hao, Jiye Zhu
BACKGROUND: Portal vein tumour thrombus (PVTT) is the main pathway of HCC intrahepatic metastasis and is responsible for the poor prognosis of patients with HCC. However, the molecular mechanisms underlying PVTT vascular metastases have not been fully elucidated. METHODS: NDRG1 expression was assessed by immunohistochemistry and immunoblotting in clinical specimens obtained from curative surgery. The functional relevance of NDRG1 was evaluated using sphere formation and animal models of tumorigenicity and metastasis...
May 10, 2023: British Journal of Cancer
Paula Peremiquel-Trillas, David Gómez, José Manuel Martínez, Sergi Fernández-González, Jon Frias-Gomez, Sonia Paytubi, Beatriz Pelegrina, Marta Pineda, Joan Brunet, Jordi Ponce, Xavier Matias-Guiu, Xavier Bosch, Silvia de Sanjosé, Laia Bruni, Laia Alemany, Laura Costas, Mireia Díaz
INTRODUCTION: New approaches are being developed to early detect endometrial cancer using molecular biomarkers. These approaches offer high sensitivities and specificities, representing a promising horizon to develop early detection strategies. OBJECTIVE: To evaluate the effectiveness and cost-effectiveness of introducing molecular testing to detect endometrial cancer in women with postmenopausal bleeding compared to the current strategy using the national healthcare service perspective...
May 10, 2023: British Journal of Cancer
Sierra Cheng, John R McLaughlin, M Catherine Brown, Hamad Al-Sawaihey, James Rutka, Eric Bouffet, Cynthia Hawkins, A Elizabeth Cairney, Adrianna Ranger, Adam J Fleming, Donna Johnston, Mark Grenberg, David Malkin, Rayjean J Hung
BACKGROUND: Studies to date have yielded inconclusive results as to whether maternal medical history during pregnancy, and a child's early-life medical history contribute to the development of childhood brain tumours (CBTs). This study examined associations between maternal and childhood medical history and the risk of CBTs. METHODS: The Childhood Brain Tumour Epidemiology Study of Ontario (CBREO) examined children 0-15 years of age with newly diagnosed CBTs from 1997 to 2003...
May 10, 2023: British Journal of Cancer
Dikshat Gopal Gupta, Neelam Varma, Sreejesh Sreedharanunni, Sarki Abba Abdulkadir, Shano Naseem, Man Updesh Singh Sachdeva, Jogeshwar Binota, Parveen Bose, Pankaj Malhotra, Alka Khadwal, Subhash Varma
BACKGROUND: Early detection of BCR::ABL1-like ALL could impact treatment management and improve the overall survival/outcome. BCR::ABL1-like ALL cases are characterised by diverse genetic alterations activating cytokine receptors and kinase signalling. Its detection is still an unmet need in low-middle-income countries due to the unavailability of a patented TLDA assay. METHODS: This study's rationale is to identify BCR::ABL1-like ALLs using the PHi-RACE classifier, followed by the characterisation of underlying adverse genetic alterations in recurrent gene abnormalities negative (RGAneg ) B-ALLs (n = 108)...
May 8, 2023: British Journal of Cancer
Mattias Hammarström, Marike Gabrielson, Alessio Crippa, Andrea Discacciati, Martin Eklund, Cecilia Lundholm, Magnus Bäcklund, Yvonne Wengström, Signe Borgquist, Jenny Bergqvist, Mikael Eriksson, José Tapia, Kamila Czene, Per Hall
BACKGROUND: Adherence to adjuvant tamoxifen therapy is suboptimal, and acceptance of tamoxifen for primary prevention is poor. Published results indicate effect of low-dose tamoxifen therapy. Using questionnaire data from a randomised controlled trial, we describe side effects of standard and low-dose tamoxifen in healthy women. METHODS: In the KARISMA trial, 1440 healthy women were randomised to 6 months of daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo...
May 6, 2023: British Journal of Cancer
Makoto Yamasaki, Hiroshi Miyata, Kotaro Yamashita, Takuya Hamakawa, Koji Tanaka, Keijiro Sugimura, Tomoki Makino, Atsushi Takeno, Osamu Shiraishi, Masaaki Motoori, Yutaka Kimura, Motohiro Hirao, Kazumasa Fujitani, Takusi Yasuda, Masahiko Yano, Hidetoshi Eguchi, Yuichiro Doki
BACKGROUND: We report the long-term results as primary endpoint in a multicentre randomized prospective Phase 2 trial which compared chemoradiotherapy (CRT) and triplet chemotherapy (CT) as the initial therapy for conversion surgery (CS) in T4b esophageal cancer (EC). METHODS: Patients with T4b EC were randomly assigned to the CRT group or CT group as initial treatment. CS was performed if resectable after initial or secondary treatment. The primary endpoint was 2-year overall survival, analysed by intention-to-treat...
May 4, 2023: British Journal of Cancer
Michael Guenther, Sai Agash Surendran, Michael Haas, Volker Heinemann, Michael von Bergwelt-Baildon, Jutta Engel, Jens Werner, Stefan Boeck, Steffen Ormanns
BACKGROUND: Targeting protein for Xenopus kinesin-like protein 2 (TPX2) overexpression in human tumours is associated with increased malignancy. Its effect on gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC) has not been studied yet. METHODS: The prognostic impact of TPX2 expression was examined in the tumour tissue of 139 patients with advanced PDAC (aPDAC) treated within the AIO-PK0104 trial or translational trials and of 400 resected PDAC (rPDAC) patients...
May 4, 2023: British Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.